Electromed Inc

Aktienanalyse zu Electromed Inc (ELMD)

$29.600

-0.530 (-1.79%)Zum Schluss

Loading chart…
High
30.660
Open
29.900
VWAP
29.73
Vol
179.74K
Mkt Cap
124.82M
Low
28.930
Amount
5.34M
EV/EBITDA, TTM
11.90

Electromed, Inc. develops, manufactures, markets and sells products that provide airway clearance therapy, including the SmartVest Airway Clearance System, to patients with compromised pulmonary function. It applies High Frequency Chest Wall Oscillation (HFCWO) technologies in pulmonary care for patients of all ages. The SmartVest Clearway System consists of an inflatable therapy garment, a programmable air pulse generator and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall. The SmartVest Clearway is designed for comfort and convenience, so patients can readily fit therapy into their daily routines. The SmartVest System is primarily prescribed for patients with bronchiectasis, cystic fibrosis, and neuromuscular conditions such as cerebral palsy and amyotrophic lateral sclerosis. It also markets the Single Patient Use (SPU) SmartVest and SmartVest Wrap to health care providers in the acute care setting.

smartvest.com

AI analysis of Electromed Inc (ELMD)

buy

Electromed Inc is a good buy right now due to its strong financial performance and positive growth indicators. The current price is $29.60, which is significantly below the analyst price target of $47, indicating a potential upside of 58.8%. Additionally, the company has reported a gross margin of 78.71% in Q4 2026, showcasing its strong profitability. However, the main risk is the recent 5-day price change of -24.97%, indicating volatility.

Bewertungskennzahlen

The current forward P/E ratio for Electromed Inc (ELMD) is 20.24, compared to its 5-year average forward P/E of 28.05.

Forward P/E

Fair
5Y Average P/E
28.05
Current P/E
20.24
Überbewertet
36.53
Unterbewertet
19.56

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
14.74
Current EV/EBITDA
11.90
Überbewertet
18.24
Unterbewertet
11.24

Forward P/S

Fair
5Y Average P/S
2.47
Current P/S
2.69
Überbewertet
3.21
Unterbewertet
1.74

Alphio AI Price Scenarios for ELMD

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%ELMD

$27.56

Szenariopreis

B

Base

Base · 50%ELMD

$23.38

Szenariopreis

B

Bear

Bear · 25%ELMD

$21.83

Szenariopreis

Event-Zeitleiste

2026-08-25 (ET)

20:00:00

Nasdaq Composite Rebounds, Micron Up 2.5%

16:30:00

Electromed Reports Q4 Revenue of $19.4M

16:30:00

Electromed President and CEO Jim Cunniff to Retire on April 2, 2027

2026-05-12 (ET)

16:30:00

Electromed Reports Q3 Revenue of $18.6M

2026-02-10 (ET)

16:20:00

Electromed Reports Q2 Revenue of $18.9M

News

ELMD FAQ — answered by Alphio AI

Electromed, Inc. develops, manufactures, markets and sells products that provide airway clearance therapy, including the SmartVest Airway Clearance System, to patients with compromised pulmonary function. It applies High Frequency Chest Wall Oscillation (HFCWO) technologies in pulmonary care for patients of all ages. The SmartVest Clearway System consists of an inflatable therapy garment, a programmable air pulse generator and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall. The SmartVest Clearway is designed for comfort and convenience, so patients can readily fit therapy into their daily routines. The SmartVest System is primarily prescribed for patients with bronchiectasis, cystic fibrosis, and neuromuscular conditions such as cerebral palsy and amyotrophic lateral sclerosis. It also markets the Single Patient Use (SPU) SmartVest and SmartVest Wrap to health care providers in the acute care setting. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).

Electromed Inc is a good buy right now due to its strong financial performance and positive growth indicators. The current price is $29.60, which is significantly below the analyst price target of $47, indicating a potential upside of 58.8%. Additionally, the company has reported a gross margin of 78.71% in Q4 2026, showcasing its strong profitability. However, the main risk is the recent 5-day price change of -24.97%, indicating volatility.

Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.

Kostenlos starten